Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance
M Kohli, I Schiller, N Dendukuri… - Cochrane Database …, 2018 - cochranelibrary.com
Cochrane Database of Systematic Reviews, 2018•cochranelibrary.com
Background Tuberculosis (TB) is the world's leading infectious cause of death.
Extrapulmonary TB accounts for 15% of TB cases, but the proportion is increasing, and over
half a million people were newly diagnosed with rifampicin‐resistant TB in 2016. Xpert®
MTB/RIF (Xpert) is a World Health Organization (WHO)‐recommended, rapid, automated,
nucleic acid amplification assay that is used widely for simultaneous detection of
Mycobacterium tuberculosis complex and rifampicin resistance in sputum specimens. This …
Extrapulmonary TB accounts for 15% of TB cases, but the proportion is increasing, and over
half a million people were newly diagnosed with rifampicin‐resistant TB in 2016. Xpert®
MTB/RIF (Xpert) is a World Health Organization (WHO)‐recommended, rapid, automated,
nucleic acid amplification assay that is used widely for simultaneous detection of
Mycobacterium tuberculosis complex and rifampicin resistance in sputum specimens. This …
Background
Tuberculosis (TB) is the world’s leading infectious cause of death. Extrapulmonary TB accounts for 15% of TB cases, but the proportion is increasing, and over half a million people were newly diagnosed with rifampicin‐resistant TB in 2016. Xpert® MTB/RIF (Xpert) is a World Health Organization (WHO)‐recommended, rapid, automated, nucleic acid amplification assay that is used widely for simultaneous detection of Mycobacterium tuberculosis complex and rifampicin resistance in sputum specimens. This Cochrane Review assessed the accuracy of Xpert in extrapulmonary specimens.
Objectives
To determine the diagnostic accuracy of Xpert a) for extrapulmonary TB by site of disease in people presumed to have extrapulmonary TB; and b) for rifampicin resistance in people presumed to have extrapulmonary TB.
cochranelibrary.com
以上显示的是最相近的搜索结果。 查看全部搜索结果